LOGIN  |  REGISTER
Viking Therapeutics
Astria Therapeutics

Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023

May 01, 2023 | Last Trade: US$0.88 0.01 -1.65

REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced its first quarter 2023 financial results will be released after market close on Monday, May 8, 2023. Starting at 5:00 pm ET on May 8, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.

A replay of the webcast will be available on http://investors.coherus.com following the conclusion of the live conference call.

Conference Call Information

When: Monday, May 8th, 2023, starting at 5:00 p.m. Eastern Time
To access the conference call, please pre-register through the following link to receive dial-in information and a personal PIN to access the live call: https://register.vevent.com/register/BI12e6d284dae8440e91891f2cef4f2097

Webcast: https://edge.media-server.com/mmc/p/ugoyrevj

The press release with the first quarter financial results and related materials will be available at https://investors.coherus.com prior to the start of the conference call.

A live and archived webcast will be available on the “Investors” section of the Coherus website at http://investors.coherus.com.

Please dial-in 15 minutes early to ensure a timely connection to the call.

Coherus Contact Information:
Marek Ciszewski, SVP Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page